2026-06-17T21:16:58Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/88222024-03-15T01:05:27Zcom_10259_4219com_10259_5086com_10259_2604col_10259_4220

Santos García, Diego Deus-Fonticoba, Teresa de Cores Bartolomé, Carlos Feal Painceiras, María Suárez Castro, Ester Canfield, Héctor Martínez Miró, Cristina Jesús, Silvia Aguilar, Miquel Pastor, Pau Planellás, Lluis L. Cosgaya, Marina García Caldentey, Juan Caballol, Núria Legarda, Inés Hernández Vara, Jorge Cabo López, Iria López Manzanares, Lydia González Aramburu, Isabel Ávila Rivera, María A. Gómez Mayordomo, Víctor Nogueira, Víctor Puente, Víctor Dotor, Julio Borrue, Carmen Solano Vila, Berta Álvarez Saúco, María Vela Desojo, Lydia Escalante Arroyo, Sonia Cubo Delgado, Esther Carrillo Padilla, Francisco Martínez Castrillo, Juan Carlos Sánchez Alonso, Pilar Alonso Losada, María Gema López Ariztegui, Nuria Gastón, Itziar Kulisevsky Bojarsky, Jaume Blázquez Estrada, Marta Seijo, Manuel Ruíz Martínez, Javier Valero, Caridad Kurtis, Mónica M. Fabregues, Oriol de González Ardura, Jessica Alonso Redondo, Rubén Ordás Bandera, Carlos Manuel López Díaz, Luis M. McAfee, Darrian Martínez Martín, Pablo Mir, Pablo COPPADIS Study Group 2024-03-14T11:48:47Z 2024-03-14T11:48:47Z 2022-05 http://hdl.handle.net/10259/8822 10.3390/diagnostics12051147 2075-4418 Objective: The aim of the present study was to analyze the progression of non-motor symptoms (NMS) burden in Parkinson’s disease (PD) patients regarding the development of motor fluctuations (MF). Methods: PD patients without MF at baseline, who were recruited from January 2016 to November 2017 (V0) and evaluated again at a 2-year follow-up (V2) from 35 centers of Spain from the COPPADIS cohort, were included in this analysis. MF development at V2 was defined as a score ≥ 1 in the item-39 of the UPDRS-Part IV, whereas NMS burden was defined according to the Non-motor Symptoms Scale (NMSS) total score. Results: Three hundred and thirty PD patients (62.67 ± 8.7 years old; 58.8% males) were included. From V0 to V2, 27.6% of the patients developed MF. The mean NMSS total score at baseline was higher in those patients who developed MF after the 2-year follow-up (46.34 ± 36.48 vs. 34.3 ± 29.07; p = 0.001). A greater increase in the NMSS total score from V0 to V2 was observed in patients who developed MF (+16.07 ± 37.37) compared to those who did not develop MF (+6.2 ± 25.8) (p = 0.021). Development of MF after a 2-year follow-up was associated with an increase in the NMSS total score (β = 0.128; p = 0.046) after adjustment to age, gender, years from symptoms onset, levodopa equivalent daily dose (LEDD) and the NMSS total score at baseline, and the change in LEDD from V0 to V2. Conclusions: In PD patients, the development of MF is associated with a greater increase in the NMS burden after a 2-year follow-up. The study was conducted according to the guidelines of the Declaration of Helsinki, and ap-proved by Comité de Ética de la Investigación Clínica de Galicia from Spain (2014/534; 2/DEC/2014). application/pdf eng MDPI Diagnostics. 2022, V. 12, n. 5, 1147 https://doi.org/10.3390/diagnostics12051147 Atribución 4.0 Internacional http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess Burden Follow-up Non-motor symptoms Motor fluctuations Parkinson’s disease Sistema nervioso-Enfermedades Medicina Neurología Nervous system-Diseases Medicine Neurology Motor Fluctuations Development Is Associated with Non-Motor Symptoms Burden Progression in Parkinson’s Disease Patients: A 2-Year Follow-Up Study info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Diagnostics 12 5